$AZN

AI Analysis

Generated on May 11, 2026

AI Score
76/ 100
Buy$AZN

AstraZeneca PLC

$AZNNASDAQHealthcareMega-Cap

AstraZeneca develops prescription medicines in oncology, cardiovascular, renal, respiratory, and immunology.

Market Cap
$220.0B
Revenue (TTM)
$49.0B
+8.0%
Net Income (TTM)
$6.5B
+12.0%
EPS (TTM)
$4.20
P/E Ratio
35.0
Dividend Yield
2.0%
52-Week Range
$58-$87
Beta
0.52
Dimension Scores
Fundamental
78
Technical
68
Sentiment
74
Risk / Reward
76
Momentum
68
FundTechSentRiskMome
Financial Health
Profitability
83strong
Growth
71moderate
Liquidity
84strong
Solvency
80strong
Efficiency
76strong

Valuation, technical analysis, investment thesis, risk assessment and more for $AZN

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.